CloudMD: Canaccord Lowers Target After Leading $55 Million Bought Deal

On March 9th, CloudMD Software & Services (TSXV: DOC)  announced that their C$55 million bought deal financing closed, with underwriters taking an additional 1.9 million shares equal to C$5.1 million.

CloudMD currently has five analysts covering the company with a weighted 12-month price target of C$3.82. This is down from last month, which was C$3.91. One analyst has a strong buy rating, while the other four have buy ratings on the name.

The street high comes from Laurentian Bank with a C$4.25 price target, and the lowest target comes from Canaccord Genuity with a C$3.50 price target. Laurentian Bank raised their price target from C$4 to C$4.25 while Canaccord downgraded the name from C$3.75 to C$3.50 after they both were a part of the underwriting, with Canaccord Genuity actually leading the underwriting.

Selkirk Copper Mines — sponsored Sponsored · Selkirk Copper Mines

Doug Taylor, Canaccord’s analyst, reiterated his speculative buy rating and headlines, “Updating model to reflect reloaded balance sheet and timing of M&A closing.” The main reason for the downgrade was due to the dilution via the financing, while they did very slightly change their full-year 2021 and 2022 revenue estimate.

Taylor believes that after the financing, the company now has on a pro-forma basis C$60 million in cash and “is well-capitalized to pursue additional M&A targets.” The company also announced that they signed a definitive agreement with IDYA4. The company did U$4.4 million in revenue with a 31% EBITDA margin in 2020. The deal is expected to close by the end of March, while Canaccord has moved back the closing date of VisionPros to late in the second quarter.

Taylor touches on the March 2nd partnership with Medavie Blue Cross. He writes, “the announcement highlights CloudMD’s increased focus on digital corporate and insurer offerings in addition to primary health services. We understand that, in recent months, CloudMD has seen success in cross-selling its broader footprint of enterprise-focused solutions to drive organic growth post-acquisition.”

Below you can see Canaccord’s slight estimate changes for the years 2021 and 2022.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Inside a Forgotten High-Grade Gold Mine in the Yukon | Blue Jay Gold [DD-on-the-GO Ep. 10]

WHICH MINING STOCKS CAN STILL RUN? | Mining Stock Mailbag [Nov. 9-13]

Silver’s Bull Market Isn’t Over | Peter Krauth

Recommended

Questcorp Begins 600 Metre Phase 2B Drill Program at La Union

Selkirk Copper Wraps 54,579 Metre Phase 2 Program at Minto, Hits 5.97% Copper Equivalent

Related News

Alphabet: Consensus Earnings Estimates For Q1 2021

Alphabet (NASDAQ: GOOG) will be reporting their first quarter financial results on April 27th after...

Monday, April 26, 2021, 11:44:00 AM

Raymond James: Village Farms Selloff Is Overdone

Village Farms International, Inc. (TSX: VFF) investors are having a rough start to the month,...

Wednesday, May 12, 2021, 02:36:00 PM

Paradigm Initiates Coverage On Trulieve With $59 Price Target

Earlier this month, Paradigm Capital initiated coverage on Trulieve Cannabis Corp (CSE: TRUL) with a...

Sunday, December 27, 2020, 01:42:00 PM

CloudMD: Canaccord Cuts Target To $0.45 Ahead of Q2 2022 Results

On Wednesday, Canaccord Genuity Capital Markets downgraded and cut their price target on CloudMD (TSXV:...

Sunday, August 21, 2022, 03:09:00 PM

Small Pharma: Canaccord Initiates Coverage With $1.00 Price Target

Canaccord Genuity recently initiated coverage on Small Pharma Inc (TSXV: DMT), a company that is...

Sunday, June 13, 2021, 01:08:00 PM